Shots:

• Nona Biosciences & Lycia Therapeutics have entered into a collaboration to advance the extracellular protein degradation technology platform
• Under the collaboration, Nona will utilize Lycia's lysosomal targeting chimeras (LYTACs) platform to discover and develop first-in-class therapeutics that degrade extracellular and membrane-bound proteins that drive a range of difficult-to-treat diseases
• Furthermore, Lycia will utilize Nona's exclusive Harbour Mice HCAb fully human antibody transgenic mice platform to explore new antibodies for its LYTAC protein degrader therapeutics

Ref: PR Newswire | Image: Nona Biosciences

Related News:- Lilly Signs a License Agreement with Lycia  to Develop Novel LYTAC Degraders

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com